Vericiguat (Verquvo) is labeled for the treatment of adults with symptomatic chronic heart failure (HF) and an ejection fraction of less than 45%. It is used to reduce the composite risk of cardiovascular death and HF-related hospitalization following a previous hospitalization for HF or the need for outpatient intravenous diuretics.¹ Vericiguat causes smooth muscle relaxation and vasodilation by stimulating soluble guanylate cyclase (which is decreased in HF), both independently and synergistically with nitric oxide, a unique mechanism.